^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | RGT-018 (SOS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
477 / 8 - Discovery of RGT-018: A potent, selective and orally bioavailable SOS1 inhibitor for mutant KRAS-driven cancers
Published date:
03/15/2023
Excerpt:
In vivo efficacy study data were generated using lung and pancreatic cancer xenograft mouse models with KRAS mutation….Robust anti-proliferation activity was observed when RGT-018 was combined with MEK, KRASG12C, EGFR or CDK2/4/6 inhibitors in vitro. Oral administration of RGT-018 inhibited tumor growth and suppressed KRAS signaling pathway activation in tumor xenografts. Furthermore, combination with MEK or KRASG12C inhibitors led to profound tumor regression.
Secondary therapy:
CDK6 inhibitor; Undisclosed EGFR inhibitor; FWD-K01; MEK Inhibitor; RLY-2139; CDK4 inhibitor
